NCT07280013 2026-03-05A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma SubjectsC4 Therapeutics, Inc.Phase 1 Recruiting60 enrolled